Ngā hua rapu - Dean Ruether

  • E whakaatu ana i te 1 - 5 hua o te 5
Whakamahine hua
  1. 1
    Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta

    Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta mā Gotto, Geoffrey T., Shea-Budgell, Melissa A., Dean Ruether, J.

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update

    Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update mā North, Scott A., Basappa, Naveen, Basiuk, Joan, Bjarnason, Georg, Breau, Rodney, Canil, Christina, Heng, Daniel, Jewett, Michael A.S., Kapoor, Anil, Kollmannsberger, Christian, Potvin, Kylea, Neil Reaume, M., Dean Ruether, J., Venner, Peter, Wood, Lori

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer

    Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer mā Howard I. Scher, Xiaoyu Jia, Kim Chi, Ronald de Wit, William R. Berry, Peter Albers, Brian S. Henick, David Waterhouse, Dean Ruether, Peter J. Rosen, Anthony A. Meluch, Luke T. Nordquist, Peter Venner, Axel Heidenreich, Luis Chu, Glenn Heller

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

    Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults mā D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika K. Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine Simmons, Denis Soulières, Emina Torlakovic, Ming‐Sound Tsao

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

    EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma mā Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, David C. Smith, Dean Ruether, Thomas W. Flaig, Joaquina Baranda, Joshua M. Lang, Elizabeth R. Plimack, Randeep Sangha, Elisabeth I. Heath, Jamie Merchan, David I. Quinn, Sandy Srinivas, Matthew I. Milowsky, Chunzhang Wu, Elaina M. Gartner, Peiying Zuo, Amal Melhem‐Bertrandt, Daniel P. Petrylak

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: